Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management by Guarneri, Valentina et al.
Comparison of HER-2 and Hormone Receptor Expression in Primary
Breast Cancers and Asynchronous Paired Metastases: Impact on
Patient Management
VALENTINA GUARNERI,a SIMONA GIOVANNELLI,a GUIDO FICARRA,b STEFANIA BETTELLI,b
ANTONINO MAIORANA,b FEDERICO PIACENTINI,a ELENA BARBIERI,a MARIA VITTORIA DIECI,a
ROBERTO D’AMICO,a GORDANA JOVIC,a PIERFRANCO CONTEa
Departments of aOncology and Hematology and bPathology, Modena University Hospital, Modena, Italy
Key Words. Breast cancer • HER-2 • Hormone receptors • Primary tumor • Metastasis biopsy
Disclosure: The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and
free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors,
planners, independent peer reviewers, or staff managers.
ABSTRACT
Introduction. The assessment of hormone receptors
(HRs) and human epidermal growth factor receptor
(HER)-2 is necessary to select patients who are candi-
dates for hormonal and anti–HER-2 therapy. The
evaluation of these parameters is generally carried
out in primary tumors and it is not clear if reassess-
ment in metastatic lesions might have an impact on
patient management. The primary aim of this analy-
sis was to compare HER-2 and HR status in primary
tumors versus metastatic sites in breast cancer pa-
tients.
Patients and Methods. Seventy-five patients with avail-
able samples from primary tumors and paired metastases
were included. HER-2 status was evaluated by immuno-
histochemistry (IHC) and/or fluorescence in situ hybrid-
ization (FISH); HR status was assessed by IHC.
Results. Nineteen percent of primary tumors were
HER-2 positive; 77% were HR positive. Sites of biop-
sied or resected metastases were: locoregional soft tis-
sues (n 30), liver (n 20), central nervous system (n
5), bone (n 5), pleura (n 4), distant soft tissues (n
3), abdomen (stomach, colon, peritoneum) (n  3),
bronchus (n 3), and bone marrow (n 2). For paired
metastases, the HER-2 status was unchanged in 84% of
cases; two patients changed from positive to negative,
while 10 patients converted from negative to positive
(agreement, 84%;   0.5681). A change in HR status
was observed in 16 cases (21%): nine cases from positive
to negative and seven cases from negative to positive
(agreement, 78.7%;   0.4158).
Conclusions. Further studies are necessary to bet-
ter define the level of discordance in HER-2 or HR
status between primary tumors and paired metasta-
ses. However, a biopsy of metastatic disease can be
recommended, if feasible with minimal invasiveness,
because treatment options might change for a signif-
icant proportion of patients. The Oncologist 2008;13:
838–844
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INTRODUCTION
Hormonal therapy and anti–human epidermal growth fac-
tor receptor (HER)-2 treatments represent the most success-
ful examples of targeted therapy for breast cancer. For at
least three decades, the expression of hormone receptors
(HRs) has been recognized as the main determinant of the
efficacy of endocrine manipulation. The last update of the
Oxford meta-analysis has shown, in30,000 patients, that
the benefit of adjuvant tamoxifen is limited to patients with
expression of HRs [1].
Similarly, in metastatic disease, the benefit of the anti–
HER-2 monoclonal antibody trastuzumab is clearly limited
to those patients with HER-2 overexpression or amplifica-
tion [2], and adjuvant studies have been performed in this
subset of patients only. The precise definition of the HR and
HER-2 status is therefore critical for the selection of appro-
priate therapies. The evaluation of these predictive param-
eters is generally carried out in the primary tumor, and this
assessment is taken into account to select treatment even in
cases of metastases that occur several years later. Several
reports have shown a lack of concordance in the expression
of these predictive factors between primary tumors and
metastatic sites [3–16]. However, these data are derived, in
most cases, from relatively small retrospective series, be-
cause sampling of metastatic sites is not routinely per-
formed in the majority of centers. In these series, the
disagreement in HER-2 expression between primary tu-
mors and distant metastases is in the range of 0%–34%.
Similarly, the expression of HRs has also shown a cer-
tain variability between primary tumors and recurrences
[15–22].
The differences between primary tumors and metastases
could be a result of genetic drift occurring during tumor
progression [8] or intratumoral heterogeneity wherein the
clone with the more aggressive phenotype starts the micro-
metastatic process from the beginning [23, 24]. Moreover,
treatments might also interfere with this process, by select-
ing resistant clones. As a matter of fact, the question of
whether or not it is appropriate to reassess HR and HER-2
expression in metastatic lesions also needs to be addressed
in the light of new therapeutic options based on the molec-
ular subtypes of breast cancer.
The aim of this study was to evaluate concordance in the
expression of HER-2 and HRs between primary breast can-
cers and asynchronous paired metastases.
METHODS
Patient Selection
The archive of the pathology division of our institution was
searched to identify all biopsies for metastases in patients
with breast cancer performed in the period 2004 –2007.
Eighty-seven patients were identified, and 75 patients with
available samples from primary tumors and who were fol-
lowed in our department were considered for this analysis.
Patients with stage IV disease at diagnosis were included
only in cases when sampling of metastases was performed
on metachronous lesions.
Study Aims
The primary aim of the present analysis was to compare the
HER-2 status of primary tumors and paired asynchronous
metastases in breast cancer patients. Secondary aims were
to compare the expression of HRs in primary tumors and
paired asynchronous metastases and to evaluate changes in
HER-2 and HR expression according to the site of sampled
metastases, the time between the primary diagnosis and me-
tastasis biopsy, and prior therapies.
Pathology
All specimens from both primary tumors and metastatic site
biopsies were analyzed at our department of pathology by a
dedicated breast pathologist. HER-2 status was evaluated
by immunohistochemistry (IHC) and/or fluorescence in
situ hybridization (FISH). HR status was measured by IHC.
All cases were re-evaluated according to the initial pro-
cedure (either IHC or FISH). Retesting was done only if the
original samples were not available or suitable for re-eval-
uation. Retesting was always done using the same assay
used in the original report, and the same assay (either FISH
or IHC) was always used in paired samples. Discordant
cases were independently reviewed by another pathologist,
blinded to the previous results.
IHC Staining
Tumor specimens were fixed in 10% neutral-buffered for-
malin for 20–28 hours before processing and embedding.
The antibodies used were: Novocastra clone CB11 (No-
vocastra Laboratories, Ltd., Newcastle upon Tyne, UK) for
the evaluation of HER-2, Ventana Medical Systems clone
6F11 (Ventana Medical Systems, Inc., Tucson, AZ) for
evaluation of the estrogen receptor (ER), and Ventana Med-
ical Systems clone 1E2 (Ventana Medical Systems, Inc.)
for evaluation of the progesterone receptor (PgR).
IHC staining was performed according to the avidin–
biotin method, using tissue sections of 3-m thickness. Af-
ter deparaffinization in xylene and graded alcohols, epitope
retrieval was performed with the Ventana CC1 reagent
buffer (pH 8, Ventana Medical Systems, Inc.) at 98°C for
60 minutes. After epitope retrieval, endogenous peroxidase
was blocked by 0.3% hydrogen peroxide for 15 minutes.
Sections were incubated with primary antibody for 30 min-
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utes at 37°C, then with the biotinylated secondary antibody
for 20 minutes at 37°C, and then in avidin–biotin complex
for a further 45 minutes. Diaminobenzidine tetrahydrochlo-
ride was used as the chromogen. For ER and PgR assess-
ment, the following parameters were recorded: the presence
or absence of an immunoreaction and the percentage of im-
munostained cells. The ER or PgR status was defined as
positive in cases where there was IHC staining in10% of
cells.
The scoring of HER-2 by IHC was evaluated semiquan-
titatively according to the following categories: 0, no mem-
brane staining; 1, partial membrane staining in10% of
tumor cells; 2, weak complete staining in10% of tumor
cells; 3, complete staining of the membrane in 10% of
tumor cells.
FISH analysis was performed using the PathVysion
HER-2 DNA Probe Kit (Vysis Inc., Downers Grove, IL)
consisting of two labeled DNA probes. The HER-2 probe,
which spans the entire her-2 gene (17q11.2-q12), was la-
beled in SpectrumOrange and the CEP 17 probe, which hy-
bridizes to the  satellite DNA located at the centromere of
chromosome 17p11.1-a11.1, was labeled in Spec-
trumGreen. Selected paraffin-embedded tissue sections of
3 m, containing representative malignant cells, were
deparaffinized in two 15-minute changes of xylene and de-
hydrated in two 5-minute changes of 100% alcohol fol-
lowed by 5-minute changes of 95% alcohol. Air-dried
tissue sections were treated with the Paraffin Pretreatment
Kit (Vysis Inc). The slides were immersed for 20 minutes in
0.2 mol/l HCl, washed with wash buffer, incubated for 30
minutes at 80°C with pretreatment solution (NaSCN),
washed with wash buffer, and finally treated in a protease I
solution (0.5 mg/ml protease buffer; pH, 2) for 8–10 min-
utes at 37°C. Ten microliters of the hybridization probe was
applied to the target area of the slide and immediately cov-
erslipped. Denaturation and hybridization of DNA were
performed using the metal block of a thermocycler (Hy-
Brite; Vysis Inc.). The denaturation was performed at 83°C
for 3 minutes and the hybridization was carried out over-
night at 37°C. After hybridization, slides were placed, for 2
minutes, in prewarmed 73°C standard saline citrate/0.3%
NP40 to remove excess of probes. The slides were air-dried
in the dark for approximately 15 minutes, and then the
1,000 ng/ml DAPI/Antifade (4.6-diamidine-2-phenylin-
dole; Vysis Inc.) counterstain was applied to the target area.
For scoring, a Zeiss Axioscope fluorescence microscope
equipped with a specially designed filter combination (Carl
Zeiss Inc., Jena, Germany) was used: the her-2 sequence
was visualized with an orange filter, the chromosome 17
centromere sequence was visualized with a green filter, and
the nuclei were identified with a DAPI filter. A triple band-
pass filter (orange, green, and DAPI; Vysis Inc.) was also
used. Hybridization signals were scored in at least 60 intact
nonoverlapping nuclei and FISH analysis was performed
by one observer using constant adjustment of the micro-
scope focus because the signals were located on different
focal plans. Overlapping nuclei were not scored. Represen-
tative images of each specimen were acquired with a high-
performance charged-coupled device camera in mono-
chromatic layers that were subsequently merged by the Quips
PathVysion Software (Vysis Inc.).
The her-2 gene status was scored as the ratio between
HER-2 red signals and CEP17 green signals. A HER-2/
CEP17 ratio2 was interpreted as positive for gene ampli-
fication.
Overall, samples were considered positive for HER-2 in
cases in which the IHC was 3, or the IHC was 2 and the
FISH was amplified, or the FISH was amplified. In case of
discordance between the IHC and FISH results, the HER-2
status was defined according to the FISH result.
Statistics
Agreement between the test results at different time points
was measured by -statistics. Comparisons of percentages
between groups were performed using the 2 test. The
Mann-Whitney test was used to compare the follow-up data
between groups. Continuous variables were compared us-
ing Student’s t-test for paired data.
RESULTS
Seventy-five metastatic breast cancer patients were in-
cluded in this analysis. The patient characteristics are sum-
marized in Table 1. For primary tumors, HER-2 was
overexpressed and/or amplified in 14 cases (19%). HER-2
was assessed by IHC in 54 patients, with the following re-
sults: 0 in 19 cases (35%), 1 in 22 cases (41%), 2 in four
cases (7%), and 3 in nine cases (17%). Forty-three pa-
tients were evaluated by FISH: 35 cases (81%) showed no
amplification and eight cases were amplified (19%).
ER and PgR expression levels were 10% in 73% and
58% of primary tumors, respectively. Overall, the ER
and/or PgR status was positive in 77% of the cases.
Sites of biopsied or resected metastases were: locore-
gional soft tissues (n 30), liver (n 20), central nervous
system (n  5), bone (n  5), pleura (n  4), distant soft
tissues (n  3), abdomen (stomach, colon, peritoneum)
(n  3), bronchus (n  3), and bone marrow (n  2). The
median time between the primary diagnosis and metastatic
site biopsy was 53.2 months (range, 7.2–308 months).
The median times between the primary diagnosis and
840 Change in HER-2 and HR Expression in Breast Cancer
 by on A
pril 27, 2009 
w
w
w
.TheO
ncologist.com
D
ow
nloaded from
 
locoregional versus distant metastatic site biopsy were 42.8
months (range, 7.2–197.4 months) and 54.2 months (range,
7.4–308.2 months), respectively (p  .144).
For paired metastases, the HER-2 status was found to be
unchanged in 63 cases (51 cases confirmed HER-2 nega-
tive, 12 cases confirmed HER-2 positive). A change in
HER-2 status was observed in 12 cases (16%): two patients
(2.7%) changed from positive to negative and 10 patients
(13.3%) changed from negative to positive (agreement,
84.00%;  0.5681).
In detail, the 12 cases with a change in her-2 status were
evaluated by FISH (eight cases), IHC (two cases), or both
IHC and FISH (two cases).
With respect to the HR status, a change in ER status was
observed in 17 cases (22%): eight patients (10%) changed
from positive to negative and nine patients (12%) changed
from negative to positive (agreement, 77.33%;  
0.4111). A change in PgR status was observed in 27 cases
(36%): 21 patients (28%) changed from positive to negative
and six patients (8%) changed from negative to positive
(agreement, 63.51%;  0.298).
Overall, when considering ER and/or PgR expression, a
change in HR status was observed in 16 cases (21%): nine
cases (12%) changed from positive to negative and seven
cases (9%) changed from negative to positive (agreement,
78.67%;  0.4158).
When considering HR expression as a continuous vari-
able, no significant difference was observed in the expres-
sion of the ER (mean expression on primary tumor 46.8%,
versus 48.3% on metastatic site biopsy; p  .788). A sig-
nificant decrease was observed in the expression of the PgR
(mean expression on primary tumor 29%, versus 19.3% on
metastatic site biopsy; p  .028).
The median interval from the primary diagnosis to me-
tastasis sampling was 53.2 months (range, 7.4 –308.2
months) in patients with no change in HER-2 status versus
52.5 months (range, 7.2–113 months) in the 12 patients
with a change in HER-2 expression (p  .644).
The median interval from the primary diagnosis to me-
tastasis sampling was 53.9 months (range, 7.4 –308.2
months) in patients with no change in HR status versus 46.6
months (range, 7.2–126.3 months) in the 16 patients with a
change in HR status (p  .442).
No differences were observed when comparing patients
with a change in HER-2 status and HR status with patients
with no change with respect to site of biopsy (locoregional
versus distant metastases) and prior therapies, as summa-
rized in Table 2.
Among the 10 patients who changed from HER-2 neg-
ative to HER-2 positive, seven subsequently received tras-
tuzumab (two of these patients received trastuzumab
followed by lapatinib). The median duration of anti–HER-2
treatment in these patients treated after a change in HER-2
status was 26weeks (range,2–108). Four patients were
still on anti–HER-2 therapy at the time of this report.
Three of the seven patients who converted from a neg-
ative to positive HR status subsequently received hormonal
therapy (median duration, 104 weeks; range, 48 –128
weeks).
Table 1. Patient characteristics
Characteristic n %
Evaluable patients 75 100
Median age at diagnosis, years (range) 53 (27–67)
Clinical stage at diagnosis
I 19 25
IIA/IIB 26 35
IIIA/IIIB 13 17
IIIC/IV 17 33
Histologic type
Ductal 60 80
Lobular 12 16
Other 3 4
Histologic grade
1/2 25 34
3 38 50
NA 12 16
Overall HER-2 status
Negative 61 81
Positive 14 19
HER-2 status by IHCa 54 100
0/1 41 76
2 4 7
3 9 17
her-2 status by FISHa 43 100
Negative 35 81
Positive 8 19
Hormone receptor status
ER positive 55 73.3
ER negative 20 26.7
ER and/or PgR positive 58 77.3
ER and PgR negative 17 22.7
Prior adjuvant chemotherapy 58 77
Prior adjuvant hormonal therapy 53 71
a Twenty-two cases with HER-2 assessment by both IHC
and FISH (17 negative and five positive).
Abbreviations: ER, estrogen receptor; FISH, fluorescence
in situ hybridization; HER-2, human epidermal growth
factor receptor 2; IHC, immunohistochemistry; NA, not
available; PgR, progesterone receptor.
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DISCUSSION
The molecular classification of breast cancer represents the
foundation of treatment selection for early and advanced
disease. The more clinically useful classification recog-
nizes three subtypes: HR positive (ER and/or PgR 10%),
HER-2 positive (IHC 3 and/or FISH amplified, irrespec-
tive of HR expression), and triple-negative tumors (ER,
PgR, and HER-2 negative). Endocrine manipulation and
anti–HER-2 agents represent the foundation of treatment in
cases of HR-positive and HER-2–positive tumors, respec-
tively, while, so far, chemotherapy is the only available op-
tion in triple-negative tumors.
Nowadays, these predictive parameters are evaluated at
the time of diagnosis in primary tumors, and, even though
the National Comprehensive Cancer Network guidelines
recommend a biopsy of metastatic deposits when feasible
[25], the practice of obtaining biopsies of metastatic lesions
varies considerably across centers; therefore, the clinical
management of the majority of patients is still based on the
initial assessment.
However, the appropriateness of this approach in clini-
cal practice can now be questioned for several reasons. First
of all, several reports showing a lack of concordance in the
expression of HER-2 and HRs between primary tumors and
disease recurrence have been published, thus weakening
the assumption that tumor phenotype is stable throughout
disease progression. Moreover, new imaging and radiolog-
ical techniques (e.g., ultrasound or computed tomography–
guided biopsy) have improved our ability to easily and
safely obtain tissue samples from metastatic sites. Finally,
the increasing use in the adjuvant setting of targeted agents
might exert selective pressure, possibly facilitating a mod-
ification in tumor phenotype.
In the present analysis, we observed a change in the ex-
pression of HER-2 from primary tumors to disease recur-
rences in 12 of the 75 evaluated patients (overall disagreement,
16%). Interestingly, in 10 patients, the HER-2 status changed
from negative to positive, while in two cases only a loss in the
expression of HER-2 was observed (one patient had received
prior trastuzumab).
In the literature, the discordance in HER-2 expression
between primary tumors and metastases, as measured by
IHC and/or FISH, is in the range of 0%–33.2% [3–16]. In
these reports, a change from negative to positive HER-2 ex-
pression as well as from positive to negative HER-2 expres-
sion has been described. In particular, the largest report
included 382 cases, evaluated by IHC. In that analysis, a
discordant HER-2 status was found in 127 patients
(33.2%): 90 cases (23.6%) changed from positive to nega-
tive while 37 cases (9.6%) changed from negative to posi-
tive [14]. None of those patients received trastuzumab prior
to metastasis sampling. That study showed the highest per-
centage of discordance compared with other similar stud-
ies. The authors acknowledge that a possible explanation
might be the possible misclassification of the 33 IHC 2
patients not confirmed by FISH. However, even when ex-
cluding these cases, the percentage of discordance remains
20%.
In our study, the expression of HRs showed disagree-
ment in 21% of the cases: nine cases (12%) changed from
positive to negative and seven cases (9%) changed from
negative to positive. Moreover, the quantitative evaluation
Table 2. Change in HER-2 and HR status by site of biopsy and prior therapies
HER-2 status HR status
No change Change p-value No change Change p-value
Site of biopsy .89 .730
Locoregional 25 5 23 7
Distant 38 7 36 9
Prior chemotherapy .188 .563
Yes 54 12 52 14
No 8 0 7 1
Prior hormonal therapy .222 .864
Yes 44 11 46 12
No 19 1 13 3
Prior trastuzumab .28 .357
Yes 2 1 3 0
No 61 11 56 16
Abbreviations: HER-2, human epidermal growth factor receptor 2; HR, hormone receptor.
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of the PgR showed a significant decrease from primary tu-
mors to metastases. Both these observations have been de-
scribed in the literature [15–22]; however, the data are more
scanty than in the studies performed on HER-2, in particu-
lar because in the older experiences the detection of HR was
performed by ligand-binding assay, which is less reliable
than IHC.
The mechanisms responsible for the change in the ex-
pression of HER-2 and HRs have yet to be completely un-
derstood. Possible explanations include genetic drift during
tumor progression, intratumoral heterogeneity, and the se-
lective pressure of therapies.
In our study, the change from a positive to negative HR
status, as well as the decreased PgR expression, might re-
flect acquired resistance to hormonal therapy. In fact, vir-
tually all the patients with HR expression in primary tumors
received hormonal therapy prior to metastasis biopsy (as
adjuvant therapy or for treatment of metastatic disease).
Less clear is the mechanism that drives the change in the
opposite direction, both for HR and HER-2 expression.
When comparing the subsets of patients who did or did
not experience a change in HER-2 status or HR expression,
no differences in terms of the site of biopsy, the interval
from the primary diagnosis to the metastasis biopsy, and
prior therapies were observed. Therefore, in our study pop-
ulation, neither the site of biopsy nor the time period seem
to impact the probability of observing a change in the ex-
pression of these parameters. However, even though no dif-
ferences were observed according to prior hormonal
therapy or chemotherapy, it must be underlined that, over-
all, all the patients included in the present analysis received
al least one anticancer therapy. Therefore, a role for treat-
ment in the observed phenomenon cannot been excluded.
Our results, together with other previously reported se-
ries, might have relevant clinical implications in patient
management. In our study, seven of 10 patients who
changed from HER-2 negative to HER-2 positive subse-
quently received anti–HER-2 therapy (five patients, trastu-
zumab only; two patients, trastuzumab followed by
lapatinib). In these patients, the median duration of anti–
HER-2 treatment was 26 weeks (range,2–108), which
is consistent with the expected time on treatment for HER-
2–positive patients. The same considerations are valid for
the three patients treated with hormonal therapy following
evidence of a change from negative to positive HR expres-
sion (median duration of hormonal therapy, 104 weeks;
range, 48–128 weeks).
In conclusion, our report confirms that, as already re-
ported by others, the biological characteristics of breast
cancer can vary between primary tumors and asynchronous
metastatic sites. All the pathological determinations were
performed at a single institution, thus minimizing the risk
for error. Of interest, the long duration of the treatments de-
cided on the basis of the molecular subtype defined by the
metastatic site biopsy indicates that this procedure might
also be appropriate when a discordance exists between the
primary tumor and metastasis assessments.
The retrospective nature of this analysis and the rela-
tively limited number of patients included do not allow us to
draw any firm conclusion. It is, however, clear that a change
in molecular subtype can occur over time and, in light of the
efficacy of targeted agents, when feasible with minimal in-
vasiveness, a biopsy of metastatic disease might increase
treatment options for a significant proportion of patients.
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